Abstract:
The present invention relates to a method for determining or making of a prognosis if a patient has cancer or is at an increased risk of having cancer, the method comprising testing for the presence of one or more cancer-associated fusion genes, or proteins derived thereof, in a sample obtained from a patient. More specifically, the present invention relates to fusion genes CLEC16A-EMP2, SNX2-PRDM6, MLL3-PRKAG2, DUS2L-PSKH1 and CLDN18-ARHGAP26 in gastric cancer. Use of the method and a kit when used in the method are also provided.
Abstract:
According to one aspect of the invention, there is provided an ellipsometry system for measuring any one or more of molecular binding, adsorption and desorption on a substrate, the system comprising: a) a cuvette comprising i) a body within which a cavity is formed and an opening on the body, wherein the cavity extends into the opening through which the substrate is immersed; ii) a window formed on each of two oppositely located walls of the body, wherein the windows are aligned to allow light to enter through one of the two windows to reflect off the portion of the substrate immersed in the cavity and exit through the other of the two windows; iii) a channel arrangement enclosed within the body of the cuvette and comprising two non-contiguous portions, wherein one of the two non-contiguous portions guides fluid into the cavity and the other non-contiguous portion guides fluid out of the cavity; b) a polarized light source disposed to provide the light that enters into one of the two windows on the body of the cuvette; and c) a detection stage disposed to receive the light that exits through the other of the two windows on the body of the cuvette, wherein the detection stage is configured to measure polarization rotation of the received light, the polarization rotation caused by any one or more of molecular binding, adsorption and desorption occurring on the substrate surface. The detection stage preferably contains a polarisation modulator, which is configured to measure polarization rotation of the received light.
Abstract:
A method for synthesizing a sugar alcohol comprising the step of hydrolyzing a polysaccharide in the presence of hydrogen ions (H+), an alcoholic reducing agent and a hydrogen transfer catalyst to form the sugar alcohol.
Abstract:
A number of cationic antimicrobial polymers have been synthesized by a condensation polymerization in bulk. The initial polymer formed has backbone tertiary nitrogens, which are subsequently quaternized using a suitable quaternizing agent (e.g., alkyl halide). The cationic polymers include polyamides, polycarbonates, polypolyureas and polyguanidiniums having a cationic repeat unit comprising the quaternary ammonium nitrogen as a backbone nitrogen. The cationic polymers can be active against Gram-negative, Gram-positive microbes, and/or fungi.
Abstract:
According to various embodiments, there is provided an electric meter including a sensor circuit configured to provide a plurality of instantaneous magnetic field measurements; a processing circuit configured to generate a time-series of magnetic field vectors, each magnetic field vector of the time-series of magnetic field vectors including the plurality of instantaneous magnetic field measurements; and a total current determination circuit configured to determine a total current, wherein the total current is a sum of currents of each branch of a plurality of branches of a power distribution network; wherein the processing circuit is further configured to compute a de-mixing matrix based on the determined total current and the time-series of magnetic field vectors, and further configured to linear transform each magnetic field vector using the de-mixing matrix to determine a current of each branch.
Abstract:
There is provided an in vitro assay for screening a test compound for toxicity in renal proximal tubular cells. The method comprises contacting a test compound with a test population of renal proximal tubular cells; and examining one or more cell morphology features, examining one or more cytoskeleton features, and/or determining cell numbers of the renal proximal tubular cells in the test population and comparing such cell morphology, arrangement of cytoskeletal components and/or cell count with the respective features of a control population. A change in one or more cell morphology features, a change in arrangement of one or more cytoskeleton features or a decrease in cell numbers of the test population relative to the control population is indicative that the test compound is toxic for renal proximal tubular cells.
Abstract:
The present invention relates to hydrogels comprising a plurality of amphiphilic peptides and/or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of amphiphilic peptides and/or peptoids is chemically cross-linked. The present invention further relates to methods for preparing such hydrogels and to various uses of such hydrogels, e.g. as cell culture substrates, for drug and gene delivery, as wound dressing, as an implant, as an injectable agent that gels in situ, in pharmaceutical or cosmetic compositions, in regenerative medicine, in tissue engineering and tissue regeneration, or in electronic devices. It also relates to a method of tissue regeneration or tissue replacement using a hydrogel in accordance with the present invention.
Abstract:
The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.
Abstract:
We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-1 positive patients.
Abstract:
An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fucα1-2Galβ1-3GlcNAc1-3Galβ1 or Fucα1-2Galβ1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.